Files and links (2)
Published VersionCC BY-NC V4.0, Open Access
Journal article
Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
Rheumatology and Therapy, Vol.10, pp.693-706
2023
PMID: 36848009
Abstract
Introduction:
There is a paucity of data on how patient characteristics may affect the long-term durability of certolizumab pegol (CZP) in patients with rheumatoid arthritis (RA). This study therefore aimed to investigate CZP durability and reasons for discontinuation over 5 years between different subgroups of patients with RA.
Methods:
Data were pooled from 27 clinical trials in RA patients. Durability was defined as the percentage of patients randomized to CZP at baseline who were still on CZP treatment at a given timepoint. Post hoc analyses of clinical trial data on CZP durability and reasons for discontinuation among different patient subgroups were conducted using Kaplan–Meier curves and Cox proportional hazards modeling. Patient subgroups included: age (18– < 45/45– < 65/ ≥ 65 years), gender (male/female), prior tumor necrosis factor inhibitor (TNFi) use (yes/no), and disease duration (< 1/1– < 5/5– < 10/ ≥ 10 years).
Results:
Among 6927 patients, the durability of CZP was 39.7% at 5 years. Patients aged ≥ 65 years had a 33% greater risk of CZP discontinuation than patients 18– < 45 years (hazard ratio [95% confidence interval]: 1.33 [1.19–1.49]) and patients with prior TNFi use had a 24% greater risk of discontinuing CZP than patients without (1.24 [1.12–1.37]). Conversely, greater durability was observed among patients who had a baseline disease duration of ≥ 1 year. Durability did not differ in the gender subgroup. Of the 6927 patients, the most common reason for discontinuation was inadequate levels of efficacy (13.5%); followed by adverse events (11.9%); consent withdrawn (6.7%); lost to follow-up (1.8%); protocol violation (1.7%); other reasons (9.3%).
Conclusions:
CZP durability was comparable with durability data on other bDMARDs in RA patients. Patient characteristics that were associated with greater durability included younger age, TNFi-naïvety, and disease duration ≥ 1 year. Findings may be helpful in informing clinicians on a patient’s likelihood of discontinuing CZP, based on their baseline characteristics.
Details
- Title
- Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
- Authors
- Vivian P Bykerk (Author) - Hospital for Special SurgeryPeter Nash (Author) - Griffith UniversityDavid Nicholls (Author) - University of the Sunshine Coast, Queensland, UniSC Clinical Trials CentreYoshiya Tanaka (Author) - University of Occupational and Environmental Health JapanKevin Winthrop (Author) - Oregon Health & Science UniversityChristina Popova (Author) - UCB PharmaNicola Tilt (Author) - UCB PharmaDerek Haaland (Author) - McMaster University
- Publication details
- Rheumatology and Therapy, Vol.10, pp.693-706
- Publisher
- Rheumatology and Therapy
- Date published
- 2023
- DOI
- 10.1007/s40744-023-00541-5
- ISSN
- 2198-6584; 2198-6576
- PMID
- 36848009
- Copyright note
- This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
- Grant note
- UCB Pharma
- Organisation Unit
- UniSC Clinical Trials Centre; University of the Sunshine Coast, Queensland
- Language
- English
- Record Identifier
- 99710097102621
- Output Type
- Journal article
Metrics
5 File views/ downloads
13 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web Of Science research areas
- Rheumatology
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites